You searched for compass - Ontario Institute for Cancer Research

Early results from COMPASS trial demonstrate benefits of using genomic sequencing to guide treatment for pancreatic cancer

Genomic profiling has allowed physicians to customize treatments for patients with many types of cancer, but bringing this technology to bear against advanced pancreatic cancer has proven to be extremely difficult. OICR’s pancreatic cancer Translational Research Initiative, called PanCuRx, has been conducting a first-of-its-kind clinical trial called COMPASS to evaluate the feasibility of using real time genomic sequencing in pancreatic cancer care. The research team recently reported early results from

OICR-supported research to help immunocompromised cancer patients get vaccinated

The Waterloo-based study will advance the use of a vaccine decision tool for healthcare professionals tailored to cancer patients’ needs. A research team at the University of Waterloo School of Pharmacy is advancing cancer care with support from OICR’s Innovation to Implementation (I2I) Awards. Cancer and its treatments can often impact a person’s immune system, leaving patients vulnerable to vaccine-preventable diseases. Researchers have found that many healthcare professionals find it

New PanCuRx Co-Lead aims to bring latest pancreatic cancer innovations to patients

Clinician Scientist Dr. Robert Grant will help lead OICR’s signature pancreatic cancer program into next phase. Dr. Robert Grant recently became Clinical Co-Lead of OICR’s cutting-edge pancreatic cancer research program, PanCuRx, following the retirement of Dr. Steven Gallinger. As a Clinician Investigator at Princess Margaret Cancer Centre (PM), Grant treats patients with pancreatic and biliary tract cancers and conducts research into integrating Big Data and AI technologies into clinical decision

Study of genome sequencing for biliary tract cancer reveals current state of precision oncology in Canada

A collaboration between OICR, University Health Network and the Marathon of Hope Cancer Centres Network can help inform the next evolution of cancer care in this country. By studying the care trajectory of Canadian patients with biliary tract cancers, a group of OICR researchers and collaborators have shown how precision oncology has the potential to transform cancer care, while also highlighting the challenges patients face to accessing it. Their study,

‘Ultrarapid’ genomic testing could shift paradigm for cancer treatment

An OICR initiative has reduced the turnaround time for whole genome and transcriptome sequencing in pancreatic cancer studies from 45 to 14 days. Every day matters in the race against cancer. Patients need access to the best, most complete information about their cancer so they can receive the best possible treatments. And the earlier they get it, the better their chances. Speed is especially important in pancreatic cancer, where even

Talent Mobilization

OICR’s Talent Mobilization initiative is a unique program supporting Ontario’s leading cancer research and clinical talent providing career critical support especially for our young talented investigators and building a community of researchers sharing their talents and ideas. OICR’s Talent Mobilization strategy encompasses OICR’s people programs spanning our: At the core of Talent Mobilization is the Scientific Consortium – the individuals who lead OICR’s cancer research community. Together with their teams,

New tech could modernize recovery from gynecological cancers

With support from FACIT, Hyivy Health aims to improve pelvic rehabilitation with a new, patient-centred device. It was painfully obvious to Rachel Bartholomew back in 2019 that women’s pelvic rehabilitation needed to be brought into the 21st century. Bartholomew was on bedrest, dealing with side effects from treatment for cervical cancer that “wreaked havoc” on her body. But she found the device that was meant to help her recover was

Pioneer in primary care oncology named to Order of Canada

Dr. Eva Grunfeld was honoured for her work translating evidence into practice to improve family medicine services for people with cancer. Years of dedicated practice and groundbreaking research made OICR Clinician Scientist Dr. Eva Grunfeld a leader in family medicine. The author of several high-impact studies, Grunfeld is widely recognized for helping improve primary care services for cancer patients, earning a Lifetime Achievement Award from the Foundation for Advancing Family

Cancer research community loses a pillar of patient partnership in Jill Hamer-Wilson

Jill Hamer-Wilson, who was a tireless advocate for lung cancer patients and a prominent patient partner in cancer research, passed away in November 2022. She served on OICR’s Patient and Family Advisory Council (PFAC) and also worked with the Canadian Cancer Trials Group, the International Lung Cancer Foundation, Canadian Cancer Clinical Trials Network, the Canadian Cancer Society and the White Ribbon Project. “Jill’s contributions to cancer research were amazing and

Patient perspectives fuelling translational OICR studies

People with lived experience of cancer are bringing crucial insights to studies aimed at making a clinical impact. The early days after Gary Davis’s leukemia diagnosis were all a blur. The retired Ottawa resident learned he had acute promyelocytic leukemia — an aggressive form of acute myeloid leukemia (AML) — in 2017 after a sudden onset of severe symptoms. Almost immediately, he was admitted to the leukemia ward at The

Join our Mailing List

Search Results for: compass